Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.

The endothelin-1/endothelin-A receptor autocrine pathway is overexpressed in ovarian carcinoma. We explored the efficacy of atrasentan (ABT-627), a small orally active endothelin- A receptor antagonist, in monotherapy and combination therapy on HEY ovarian carcinoma xenografts. Atrasentan (2 mg/kg per 24 hours i.p. for 21 days) induced similar inhibition of tumor growth as paclitaxel (20 mg/kg i.v. three times a day every 4 days) with a reduction of 65% compared to control. The co-administration of atrasentan enhanced the efficacy of cytotoxic agents, such as taxanes or platinum compounds. Administration of atrasentan in combination with paclitaxel caused a strong antitumor effect. Remarkably, four of ten mice bearing HEY xenografts had no histological evidence of tumors. Tumor growth inhibition was accompanied by a significant decrease of molecular effectors involved in angiogenesis and invasion and by enhanced tumor cell apoptosis. Moreover, although cisplatinum as a single agent (5 mg/kg i.p. on day 1) markedly inhibited HEY tumors, atrasentan was very effective in potentiating this effect, with partial or complete tumor regression. The antitumor, anti-angiogenic, and apoptotic activities obtained with atrasentan and the enhanced efficacy of cytotoxic agents provide a rationale for its clinical evaluation in ovarian carcinoma.
AuthorsLaura Rosanò, Francesca Spinella, Valeriana Di Castro, Pier Giorgio Natali, Anna Bagnato
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 44 Suppl 1 Pg. S132-5 (Nov 2004) ISSN: 1533-4023 [Electronic] United States
PMID15838262 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Antineoplastic Agents, Phytogenic
  • Endothelin A Receptor Antagonists
  • Pyrrolidines
  • Receptor, Endothelin A
  • Paclitaxel
  • Cisplatin
  • atrasentan
  • Angiogenesis Inhibitors (administration & dosage)
  • Animals
  • Antineoplastic Agents, Phytogenic (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Apoptosis (drug effects)
  • Cell Line, Tumor
  • Cisplatin (administration & dosage)
  • Endothelin A Receptor Antagonists
  • Female
  • Humans
  • Injections, Intraperitoneal
  • Injections, Intravenous
  • Mice
  • Mice, Nude
  • Neoplasm Invasiveness
  • Neovascularization, Pathologic (prevention & control)
  • Ovarian Neoplasms (blood supply, metabolism, pathology, prevention & control)
  • Paclitaxel (administration & dosage)
  • Pyrrolidines (administration & dosage)
  • Receptor, Endothelin A (metabolism)
  • Time Factors
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: